Dennis C. Harrer - Search Results

Year	Number of Results
2017	1
2018	2
2019	4
2020	1
2021	3
2022	7
2023	8
2024	3

1

Drug Repurposing by Tumor Tissue Editing.

Lüke F, Harrer DC, Pantziarka P, Pukrop T, Ghibelli L, Gerner C, Reichle A, Heudobler D. Lüke F, et al. Front Oncol. 2022 Jun 24;12:900985. doi: 10.3389/fonc.2022.900985. eCollection 2022. Front Oncol. 2022. PMID: 35814409 Free PMC article. Review.

2

Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges.

Harrer DC, Li SS, Kaljanac M, Barden M, Pan H, Abken H. Harrer DC, et al. Front Immunol. 2023 Nov 27;14:1321596. doi: 10.3389/fimmu.2023.1321596. eCollection 2023. Front Immunol. 2023. PMID: 38090558 Free PMC article. Review.

3

IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities.

Harrer DC, Bezler V, Hartley J, Herr W, Abken H. Harrer DC, et al. Front Immunol. 2023 May 23;14:1185618. doi: 10.3389/fimmu.2023.1185618. eCollection 2023. Front Immunol. 2023. PMID: 37287982 Free PMC article.

4

Answer to May 2023 Photo Quiz.

Ruegamer T, Harrer DC, Simon M, Sandner AS, Wolff D, Grube M, Jantsch J. Ruegamer T, et al. J Clin Microbiol. 2023 May 23;61(5):e0134022. doi: 10.1128/jcm.01340-22. Epub 2023 May 23. J Clin Microbiol. 2023. PMID: 37219090 Free PMC article.

5

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy.

Harrer DC, Dörrie J, Schaft N. Harrer DC, et al. Int J Mol Sci. 2023 Jan 25;24(3):2342. doi: 10.3390/ijms24032342. Int J Mol Sci. 2023. PMID: 36768665 Free PMC article. Review.

6

CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.

Harrer DC, Dörrie J, Schaft N. Harrer DC, et al. Int J Mol Sci. 2019 Nov 26;20(23):5942. doi: 10.3390/ijms20235942. Int J Mol Sci. 2019. PMID: 31779130 Free PMC article. Review.

7

Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race.

Harrer DC, Dörrie J, Schaft N. Harrer DC, et al. Hum Gene Ther. 2018 May;29(5):547-558. doi: 10.1089/hum.2017.236. Epub 2018 Feb 27. Hum Gene Ther. 2018. PMID: 29320890 Review.

8

Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance.

Harrer DC, Lüke F, Pukrop T, Ghibelli L, Reichle A, Heudobler D. Harrer DC, et al. Cancers (Basel). 2023 Dec 29;16(1):180. doi: 10.3390/cancers16010180. Cancers (Basel). 2023. PMID: 38201607 Free PMC article. Review.

9

Photo Quiz: Gram-Positive Meningitis following Allogeneic Stem Cell Transplantation.

Ruegamer T, Harrer DC, Simon M, Sandner AS, Wolff D, Grube M, Jantsch J. Ruegamer T, et al. J Clin Microbiol. 2023 May 23;61(5):e0133922. doi: 10.1128/jcm.01339-22. Epub 2023 May 23. J Clin Microbiol. 2023. PMID: 37219091 Free PMC article. No abstract available.

10

Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis.

Harrer DC, Jakob M, Vogelhuber M, Lüke F, Utpatel K, Corbacioglu S, Herr W, Reichle A, Heudobler D. Harrer DC, et al. Leuk Lymphoma. 2022 Dec;63(12):2858-2868. doi: 10.1080/10428194.2022.2095627. Epub 2022 Jul 12. Leuk Lymphoma. 2022. PMID: 35819881

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

28 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year